Skip to main content
SpringerLink
Log in

Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

MicroRNA-183 (miR-183) has been demonstrated to be a tumor suppressor miRNA in inhibition of migration and invasion of osteosarcoma by targeting an oncogene Ezrin. The aim of the present study was to determine the correlation of combined miR-183 and Ezrin mRNA expression with clinicopathologic features and prognosis in patients with osteosarcomas. Expressions of MiR-183 and Ezrin mRNA were both examined using quantitative real-time reverse transcriptase-polymerase chain reaction analysis in 68 specimens from patients with osteosarcomas. MiR-183 and Ezrin mRNA expression levels were, respectively, lower and higher in osteosarcoma tissues than those in noncancerous bone tissues significantly (both P < 0.001). Notably, the downregulation of miR-183 was negatively correlated with the upregulation of Ezrin mRNA in osteosarcoma tissues (r = −0.66, P = 0.01). In addition, the combined miR-183 downregulation and Ezrin upregulation (miR-183-low/Ezrin-high) was significantly associated with high tumor grade (P = 0.02), poor response to chemotherapy (P = 0.01), positive metastasis (P = 0.006) and recurrence (P = 0.008). Moreover, miR-183/Ezrin expression and the status of metastasis were both found to be independent prognostic factors for overall survival (P = 0.02 and 0.01, respectively) and disease-free survival (both P = 0.02). Our findings showed that the aberrant expression of miR-183 and its target gene Ezrin may play a crucial role in the development and progression of human osteosarcoma. More interestingly, the dysregulation of miR-183/Ezrin axis may be related to the prediction of aggressiveness and poor prognosis for patients with this lethal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.

    Article  CAS  PubMed  Google Scholar 

  2. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137:89–99.

    Article  CAS  PubMed  Google Scholar 

  3. Osborne TS, Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol. 2012;146:132–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Poletajew S, Fus L, Wasiutyński A. Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors. Ortop Traumatol Rehabil. 2011;13:537–45.

    Article  PubMed  Google Scholar 

  5. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011;28:493–503.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Chou J, Shahi P, Werb Z. MicroRNA-mediated regulation of the tumor microenvironment. Cell Cycle. 2013;12:3262–71.

    Article  PubMed  Google Scholar 

  7. Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol. 2013;34:2093–8.

    Article  CAS  PubMed  Google Scholar 

  8. Zhou G, Shi X, Zhang J, Wu S, Zhao J. MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review. J Int Med Res. 2013;41:1–12.

    Article  CAS  PubMed  Google Scholar 

  9. Liang W, Gao B, Fu P, Xu S, Qian Y, Fu Q. The miRNAs in the pathgenesis of osteosarcoma. Front Biosci. 2013;18:788–94.

    Article  CAS  Google Scholar 

  10. Tian Q, Jia J, Ling S, Liu Y, Yang S, Shao Z. A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol. 2013. doi:10.1016/j.ejso.2013.08.024.

  11. Tang M, Lin L, Cai H, Tang J, Zhou Z. MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma. Onco Targets Ther. 2013;6:833–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  12. Yuan J, Chen L, Chen X, Sun W, Zhou X. Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 2012;40:2090–7.

    Article  CAS  PubMed  Google Scholar 

  13. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58:2170–5.

    CAS  PubMed  Google Scholar 

  14. Motoyama K, Inoue H, Takatsuno Y, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34:1069–75.

    CAS  PubMed  Google Scholar 

  15. Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008;68:664–73.

    Article  CAS  PubMed  Google Scholar 

  16. Zhou T, Zhang G-J, Zhou H, Xiao H-X, Li Y. Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 2013. doi:10.1097/MEG.0000000000000002.

  17. Ueno K, Hirata H, Shahryari V, et al. MicroRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013;108:1659–67.

    Article  CAS  PubMed  Google Scholar 

  18. Tanaka H, Sasayama T, Tanaka K, et al. MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells. J Neurooncol. 2013;111:273–83.

    Article  CAS  PubMed  Google Scholar 

  19. Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett. 2008;582:3663–8.

    Article  CAS  PubMed  Google Scholar 

  20. Zhao H, Guo M, Zhao G, et al. miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med. 2012;30:1013–20.

    CAS  PubMed  Google Scholar 

  21. Zhu J, Feng Y, Ke Z, et al. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 2012;180:2440–51.

    Article  CAS  PubMed  Google Scholar 

  22. Shang X, Wang Y, Zhao Q, et al. siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells. Mol Cell Biochem. 2012;364:363–71.

    Article  CAS  PubMed  Google Scholar 

  23. Li H, Min D, Zhao H, et al. The prognostic role of ezrin immunoexpression in osteosarcoma: a meta-analysis of published data. PLoS ONE. 2013;8:e64513.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Wang Z, He ML, Zhao JM, Qing HH, Wu Y. Meta-analysis of associations of the ezrin gene with human osteosarcoma response to chemotherapy and prognosis. Asian Pac J Cancer Prev. 2013;14:2753–8.

    Article  PubMed  Google Scholar 

  25. Ren L, Hong SH, Chen QR, et al. Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma. Cancer Res. 2012;72:1001–12.

    Article  CAS  PubMed  Google Scholar 

  26. Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97:3068–75.

    Article  CAS  PubMed  Google Scholar 

  27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402–8.

    Article  CAS  PubMed  Google Scholar 

  28. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.

    Article  CAS  PubMed  Google Scholar 

  29. Jörgren F, Nilbert M, Rambech E, Bendahl PO, Lindmark G. Ezrin expression in rectal cancer predicts time to development of local recurrence. Int J Colorectal Dis. 2012;27:893–9.

    Article  PubMed  Google Scholar 

  30. Arumugam P, Partelli S, Coleman SJ, et al. Ezrin expression is an independent prognostic factor in gastro-intestinal cancers. J Gastrointest Surg. 2013;17:2082–91.

    Google Scholar 

  31. Gschwantler-Kaulich D, Natter C, Steurer S, et al. Increase in ezrin expression from benign to malignant breast tumours. Cell Oncol. 2013;36:485–91.

    Google Scholar 

  32. Saito S, Yamamoto H, Mukaisho K, et al. Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma. PLoS ONE. 2013;8:e54881.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Lee HW, Kim EH, Oh MH. Clinicopathologic implication of ezrin expression in non-small cell lung cancer. Korean J Pathol. 2012;46:470–7.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Fadiel A, Chen Z, Ulukus E, Ohtani K, Hatami M, Naftolin F. Ezrin overexpression by transformed human ovarian surface epithelial cells, ovarian cleft cells, and serous ovarian adenocarcinoma cells. Reprod Sci. 2012;19:797–805.

    Article  PubMed  Google Scholar 

  35. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005;65:2406–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Orthopedics Spine Surgery, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830000, Xinjiang, China

    Yisila Mu, Haoshaqiang Zhang, Lixin Che & Kun Li

Authors
  1. Yisila Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haoshaqiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lixin Che
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kun Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mu, Y., Zhang, H., Che, L. et al. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. Med Oncol 31, 821 (2014). https://doi.org/10.1007/s12032-013-0821-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0821-3

Keywords

Search

Navigation